BRPI0821357A2 - derivados de oxadiazois de triazol - Google Patents

derivados de oxadiazois de triazol

Info

Publication number
BRPI0821357A2
BRPI0821357A2 BRPI0821357A BRPI0821357A BRPI0821357A2 BR PI0821357 A2 BRPI0821357 A2 BR PI0821357A2 BR PI0821357 A BRPI0821357 A BR PI0821357A BR PI0821357 A BRPI0821357 A BR PI0821357A BR PI0821357 A2 BRPI0821357 A2 BR PI0821357A2
Authority
BR
Brazil
Prior art keywords
oxadiazo
triazole
derivatives
triazole oxadiazo
oxadiazo derivatives
Prior art date
Application number
BRPI0821357A
Other languages
English (en)
Inventor
Bombrun Agnés
Quattropani Anna
Baker-Glenn Charles
Knight Chris
Cleva Christophe
Rouse Craig
Marin Delphine
Sebille Eric
Schwarz Matthias
Blackaby Wesley
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of BRPI0821357A2 publication Critical patent/BRPI0821357A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0821357A 2007-12-21 2008-12-17 derivados de oxadiazois de triazol BRPI0821357A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07150311 2007-12-21
US6638508P 2008-02-20 2008-02-20
PCT/EP2008/067776 WO2009080663A1 (en) 2007-12-21 2008-12-17 Triazole oxadiazoles derivatives

Publications (1)

Publication Number Publication Date
BRPI0821357A2 true BRPI0821357A2 (pt) 2017-05-23

Family

ID=39367513

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821357A BRPI0821357A2 (pt) 2007-12-21 2008-12-17 derivados de oxadiazois de triazol

Country Status (13)

Country Link
US (1) US8202856B2 (pt)
EP (1) EP2250165B1 (pt)
JP (1) JP5451633B2 (pt)
KR (1) KR20100110834A (pt)
CN (1) CN101918395B (pt)
AR (1) AR070043A1 (pt)
AU (1) AU2008340113B2 (pt)
BR (1) BRPI0821357A2 (pt)
CA (1) CA2710345C (pt)
EA (1) EA020887B1 (pt)
IL (1) IL206514A (pt)
MX (1) MX2010007026A (pt)
WO (1) WO2009080663A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702974A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amino 1,2,4-triazole derivatives as modulators of mglur5
WO2009054791A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
ES2405054T3 (es) * 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20140235588A1 (en) * 2013-02-15 2014-08-21 Allergan, Inc. Substituted 1h-pyrazol-1,2,4-oxadiazole derivatives as sphingosine receptor modulators
WO2014127149A1 (en) * 2013-02-15 2014-08-21 Allergan, Inc. Substituted 4,5-dihydropyrazole-1,2,4-oxadiazole derivatives as sphingosine receptor modulators
WO2015126912A1 (en) * 2014-02-18 2015-08-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Marinopyrrole derivatives and methods of making and using same
EP3265088A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
EP3265457A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
TWI886480B (zh) * 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
US12606548B2 (en) 2019-10-07 2026-04-21 Fmc Corporation Fungicidal oxadiazoles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448193T1 (de) * 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
DE60329073D1 (de) * 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
EP4101846B1 (en) * 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US20080306124A1 (en) * 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
EA200802058A1 (ru) * 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
US8404676B2 (en) 2007-10-04 2013-03-26 Merck Serono Sa Oxadiazole diaryl compounds
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物

Also Published As

Publication number Publication date
CA2710345C (en) 2016-11-15
EP2250165B1 (en) 2018-07-25
WO2009080663A1 (en) 2009-07-02
MX2010007026A (es) 2010-10-05
AR070043A1 (es) 2010-03-10
EP2250165A1 (en) 2010-11-17
US8202856B2 (en) 2012-06-19
CN101918395B (zh) 2014-04-16
EA020887B1 (ru) 2015-02-27
CA2710345A1 (en) 2009-07-02
KR20100110834A (ko) 2010-10-13
JP5451633B2 (ja) 2014-03-26
AU2008340113B2 (en) 2014-01-09
JP2011506559A (ja) 2011-03-03
AU2008340113A1 (en) 2009-07-02
IL206514A0 (en) 2010-12-30
US20100305092A1 (en) 2010-12-02
CN101918395A (zh) 2010-12-15
EA201070779A1 (ru) 2011-02-28
IL206514A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
HUS2000031I1 (hu) Benzimidazol-származékok
IL195278A0 (en) Triazole derivatives ii
EP1988083A4 (en) triazole
IL241729A0 (en) Triazole macrocyclization systems
ZA201104423B (en) Oxadiazole derivatives
NL2000627A1 (nl) Cycloalkylaminoderivaten.
ZA201001228B (en) Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide derivatives
ZA201003125B (en) Imidazole derivatives
TWI348908B (en) Imidazolidinone derivatives
ATE522523T1 (de) 1,3,5-trisubstituiertes triazolderivat
ZA200806358B (en) Triazole Derivatives
BRPI0914121A2 (pt) derivado de triazol ou sal do mesmo
ZA201002439B (en) Novel imidazole derivatives
BRPI0811103A2 (pt) Compostos triazol para tratamento de formação de biopelícula
IL193475A0 (en) Benzimidazole derivatives
EP2172454A4 (en) benzimidazole derivative
ZA201002580B (en) Heterocyclic derivatives
IL205149A0 (en) Novel imidazole derivatives
PT2173756E (pt) Derivados de macrolactonas
IL184559A0 (en) Imidazole derivatives
DE502006005182D1 (de) Heterocyclylamid-substituierte imidazole
DK2155715T3 (da) ((Phenyl)imidazolyl)methylheteroarylforbindelser
EP2172458A4 (en) pyrazolone
HK1146275A (en) Triazole oxadiazoles derivatives
ZA200908626B (en) Benzimidazole Derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]